Status:
COMPLETED
Seroprevalence of SARS-Cov-2 Antibodies in Children
Lead Sponsor:
Queen's University, Belfast
Collaborating Sponsors:
Belfast Health and Social Care Trust
Conditions:
COVID
Corona Virus Infection
Eligibility:
All Genders
1-15 years
Brief Summary
It is unknown what proportion of healthy children have been exposed to SARS-Cov-2 and how many have antibodies. The aim of this study is to follow a cohort of healthy children over six months and meas...
Detailed Description
Coronaviruses are non-segmented positive-stranded RNA viruses with a roughly 30 kb genome. The majority of coronaviruses cause disease in a specific host species but some have infected humans by cross...
Eligibility Criteria
Inclusion
- Healthy children of healthcare professionals.
- Exclusion Criteria:
- Not currently receiving antibiotics, not admitted to hospital within the last seven days, not receiving immunosuppressive drugs and never diagnosed with a malignancy.
- Admitted children with paediatric multisystem inflammatory syndrome and admitted children with other serious infections.
Exclusion
Key Trial Info
Start Date :
May 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 14 2023
Estimated Enrollment :
1100 Patients enrolled
Trial Details
Trial ID
NCT04347408
Start Date
May 6 2020
End Date
November 14 2023
Last Update
December 7 2023
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Belfast Hospital for Sick Children
Belfast, United Kingdom, BT126BA
2
University Hospital of Wales
Cardiff, United Kingdom
3
Royal Hospital for Children
Glasgow, United Kingdom
4
Public Health England
London, United Kingdom